A brief of the announcement out this morning on IMU, which I think RNO still holds 25m shares in.
Could give RNO a bit of extra cash down the road if they need some
Imugene Extends Partnership with The Medical University of Vienna to
Develop Cutting-Edge Mimotope Immuno-Oncology Platform
• Partnership to deliver a pipeline of new “Mimotope” immuno-oncology B cell
vaccines against novel oncology targets
• Imugene to own the IP in the mimotope vaccines created within the partnership
• Mimotopes to be part of the next generation of the high value and rapidly
expanding immuno-oncology treatment paradigm
• Imugene has the right to select innovative vaccine candidates against a variety
of tumors
• This extends Imugene's already established collaboration with the Medical
University of Vienna with the Her-Vaxx immuno-oncology vaccine to be back in
the clinic in 2016
Regards
Dabru
RNO Price at posting:
2.9¢ Sentiment: Hold Disclosure: Held
